Anthera Pharma announces positive outcome of interim futility analysis in phase 3 study
Anthera announced a positive outcome of the pre-specified interim futility analysis for the RESULT Phase 3 clinical study of Sollpura for treatment of Exocrine Pancreatic Insufficiency. Based on the interim futility analysis, the study will proceed with topline data expected in Q1 2018. December 11, 2017